Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Nov 15;230(5):1262-1270.
doi: 10.1093/infdis/jiae170.

Safety and Immunogenicity of the H56:IC31 Tuberculosis Vaccine Candidate in Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis: A Phase 1 Randomized Trial

Dereck Tait  1 , Andreas Diacon  2 , Álvaro H Borges  3 , Elana van Brakel  4 , David Hokey  5 , Kathryn T Rutkowski  4   5 , Devin J Hunt  4 , Marisa Russell  4 , Peter L Andersen  6   7 , Ingrid Kromann  8 , Morten Ruhwald  3   9 , Gavin Churchyard  10   11   12 , Rodney Dawson  13
Affiliations
Clinical Trial

Safety and Immunogenicity of the H56:IC31 Tuberculosis Vaccine Candidate in Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis: A Phase 1 Randomized Trial

Dereck Tait et al. J Infect Dis. .

Abstract

Background: H56:IC31 is a candidate vaccine against tuberculosis (TB) with the potential to reduce TB recurrence rate. It is thus important for future clinical trials to demonstrate safety and immunogenicity of H56:IC31 in individuals treated for TB.

Methods: Twenty-two adults confirmed to be Mycobacterium tuberculosis negative (by 2 GeneXpert tests or 2 sputum cultures) after 4-5 months of TB treatment, and not more than 28 days after completion of TB treatment, were randomized to receive 2 doses of H56:IC31 (5 mg H56:500 nmol IC31; n = 16) or placebo (n = 6) 56 days apart. Participants were followed for 420 days for safety and immunogenicity.

Results: H56:IC31 vaccination was associated with an acceptable safety profile, consisting mostly of mild self-limited injection site reactions. No serious adverse events or vaccine-related severe adverse events were reported. H56:IC31 induced a CD4+ T-cell response for Ag85B and ESAT-6, with ESAT-6 being immunodominant, which persisted through 6 months after the last vaccination. There was some evidence of CD8+ T-cell responses for both Ag85B and ESAT-6, but to a lesser extent than CD4+ responses.

Conclusions: H56:IC31 was associated with an acceptable safety profile, and induced a predominant CD4+ T-cell response, in adults recently treated for drug-susceptible, uncomplicated pulmonary TB.

Clinical trials registration: NCT02375698.

Keywords: H56:IC31; immunity; safety; tuberculosis; vaccine.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. P. L. A., I. K., M. R., and A. H. B. were employed at SSI, the developer of H56:IC31. P. L. A. is the inventor of patents related to H56:IC31. All rights have been assigned to SSI, a Danish not-for-profit institute under the Ministry of Health. D. T. was employed by Aeras (now IAVI) during the conduct of this study and is now an independent consultant. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Publication types

MeSH terms

Substances

Associated data